BPI-572270

PreclinicalSmall molecule

BPI-572270 is one of 62 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Patients With Advanced Solid TumorsNot yet recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Recruiting

Patients With Advanced Solid TumorsPreclinical

Not yet recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Avastin

Roche

Phase 2

10 3

Herceptin

Roche

Phase 2

6 4

Lynparza

AstraZeneca

Phase 2

4 5

Yervoy

Bristol-Myers Squibb

Phase 2

4 6

Beyfortus

BeiGene

Phase 2

3 7

Perjeta

Roche

Phase 2

2 8

Ibrance

Pfizer

Phase 2

2 9

Cyramza

Eli Lilly

Phase 2

1 10

Adriamycin

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07435038

Clinical

Trials by Indication[1]

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.

Recruiting·BBetta Pharmaceuticals Co., Ltd.·Preclinical·NCT07435038·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BPI-572270. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BPI-572270 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BPI-572270. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Betta Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBetta Pharmaceuticals Co., Ltd.

BPI-572270

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News